Definitive Contract 75N91024C00087
Award Date
9/16/24
Potential Completion Date
9/15/26
Potential Value
$2M
Federal Agency
National Cancer Institute
Awardee
Boston Cell Standards Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Sharon, MA 02067, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
11
Legislative Mandate
Employment Eligibility Verification
National Interest Action
Not listed
Research Type
SBIR Program Phase II Action
Primary Consortia Member
Not listed
Similar Awards
This $385,889 firm fixed price Phase I SBIR contract was awarded by the National Cancer Institute (NCI) to Boston Cell Standards Inc., a for-profit manufacturer of medical devices, diagnostics, and related services. Boston Cell Standards was selected under a small business set-aside to develop quantitative traceable reference materials as medical device development tools for tissue biomarkers in cancer detection. Through this prime contract, Boston Cell Standards will support NCI's cancer...
<p>The National Cancer Institute (NCI) awarded a $249,792 Small Business Innovation Research (SBIR) Phase I contract to Biotex, Inc. to develop "Instruments and Devices that Preserve Molecular Profiles in Tumors" under SBIR Topic 257. The contract is a firm-fixed-price definitive contract with a period of performance ending on June 30, 2010. This SBIR contract supports the NCI's research objectives related to advancing cancer diagnostics and therapeutics.</p>
<p>The National Cancer Institute (NCI) awarded a Small Business Innovation Research (SBIR) Program Phase I contract to Nanoscale Corporation for the development of a rapid in vitro screening assay to detect cancer biomarkers in urine and blood. The $150,000.00 firm-fixed-price contract has a completion date of May 2, 2013. This SBIR contract is part of the NCI's efforts to support small businesses in the development of innovative cancer-related technologies.</p>
This is a $273,600 firm-fixed-price definitive contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to JBS Science Inc., a small business biotechnology company. The contract is for the development of a cell-free circulating DNA-based assay for liver cancer screening. This award supports NCI's efforts to advance innovative molecular diagnostic technologies for cancer detection and monitoring. As a small business set-aside contract, the...
This is a $197,673 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a part of the Department of Health and Human Services (HHS), to Molecular Express, Inc., a minority-owned and self-certified small disadvantaged business. The contract is for the development of a commercial point-of-care device capable of electronically sensing tumor cells and molecular cancer biomarkers in a patient's circulating peripheral blood. This research project...
The National Cancer Institute (NCI) awarded a $353,102 Firm Fixed Price contract to Angstrom Research Inc., a self-certified small disadvantaged business, for a Phase I SBIR (Small Business Innovation Research) Concept Award. The contract, identified as 75N91024C00012, is part of the NCI's SBIR program and is focused on the development of innovative therapeutic technologies, devices, or diagnostics for the treatment, detection, and diagnosis of Pediatric Cancers and/or Rare Cancers. This is a...
<p>The National Cancer Institute (NCI), a civilian federal agency, awarded a $1,416,758.40 Cost Plus Fixed Fee contract to Sensopath Technologies, Inc., a Woman Owned Small Business, for a Small Business Innovation Research (SBIR) Program Phase II action. The contract, which has a total small business set aside, was awarded on September 28, 2012 with an ultimate completion date of May 22, 2015. The contract delivers research and development services under the SBIR program.</p>
The U.S. National Cancer Institute awarded a Small Business Innovation Research (SBIR) Phase I contract to Celldex Therapeutics, Inc. in the amount of $199,398.00 on September 20, 2012. The contract is for "OTHER FUNCTIONS - R & D BIOMEDICAL (BASIC RESEARCH)" and has a firm fixed price pricing type. The contract has an ultimate completion date of August 23, 2013. This SBIR Phase I award supports basic research and development activities at Celldex Therapeutics, a for-profit small...
This is a Small Business Innovation Research (SBIR) Phase II contract awarded by the National Cancer Institute (NCI), a civilian agency under the U.S. Department of Health and Human Services. The contract, valued at $298,601, was awarded to Mediomics LLC, a woman-owned small business, for the "Development of Blood-Based Methods for the Detection of Cancer Recurrence in Post-Therapy Breast Cancer Patients." The contract was set aside for small businesses and is a Definitive Contract...
This is a $400,000.00 Small Business Innovation Research (SBIR) Phase I contract awarded by the National Cancer Institute (NCI), a component of the National Institutes of Health (NIH), to Biosensics LLC, a small business located in Newtonville, Massachusetts. The contract is for the development of an automated screening platform to enable early identification of malnutrition in cancer patients. This contract award is part of the FY24 SBIR solicitation, which covers a variety of research topics...